{
    "root": "30b09e30-01bd-efc4-e063-6394a90aabc3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Irinotecan hydrochloide",
    "value": "20250319",
    "ingredients": [
        {
            "name": "LACTIC ACID, UNSPECIFIED FORM",
            "code": "33X04XA5AT"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "IRINOTECAN HYDROCHLORIDE",
            "code": "042LAQ1IIS"
        }
    ],
    "indications": "irinotecan hydrochloride injection indicated component first-line therapy combination 5-fluorouracil ( 5-fu ) leucovorin ( lv ) patients metastatic carcinoma colon rectum . irinotecan hydrochloride injection indicated patients metastatic carcinoma colon rectum whose disease recurred progressed following initial fluorouracil-based therapy .",
    "contraindications": "colorectal cancer combination regimen 1 : irinotecan hydrochloride injection 125 mg/m 2 intravenous infusion 90 minutes days 1 , 8 , 15 , 22 lv 20 mg/m 2 intravenous bolus infusion days 1 , 8 , 15 , 22 followed 5-fu intravenous bolus infusion days 1 , 8 , 15 , 22 every 6 weeks . ( 2.1 ) colorectal cancer combination regimen 2 : irinotecan hydrochloride injection 180 mg/m 2 intravenous infusion 90 minutes days 1 , 15 , 29 lv 200 mg/m 2 intravenous infusion 2 hours days 1 , 2 , 15 , 16 , 29 , 30 followed 5-fu 400 mg/m 2 intravenous bolus infusion days 1 , 2 , 15 , 16 , 29 , 30 5-fu 600 mg/m 2 intravenous infusion 22 hours days 1 , 2 , 15 , 16 , 29 , 30 . ( 2.1 ) colorectal cancer single agent regimen 1 : irinotecan hydrochloride injection 125 mg/m 2 intravenous infusion 90 minutes days 1 , 8 , 15 , 22 2-week rest . ( 2.2 ) colorectal cancer single agent regimen 2 : irinotecan hydrochloride injection 350 mg/m 2 intravenous infusion 90 minutes day 1 every 3 weeks . ( 2.2 )",
    "warningsAndPrecautions": "irinotecan hydrochloride injection , usp supplied sterile , pale yellow , clear , aqueous solution available single-dose brown glass vials following package sizes : presentation ndc code 2 ml-fill vial containing 40 mg/2 ml ( 20 mg/ml ) irinotecan hydrochloride injection ndc 68001-480-35 5 ml-fill vial containing 100 mg/5 ml ( 20 mg/ml ) irinotecan hydrochloride injection ndc 68001-480-22 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect light . keep vial carton time . inspect vial damage visible signs leaks removing carton . damaged , incinerate unopened package . irinotecan hydrochloride hazardous . follow special handling disposal procedures 1 .",
    "adverseReactions": "\u2022 irinotecan hydrochloride injection contraindicated patients known hypersensitivity excipients .",
    "indications_original": "Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.\n                     Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.",
    "contraindications_original": "Colorectal cancer combination regimen 1: Irinotecan hydrochloride injection 125 mg/m 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 with LV 20 mg/m 2 intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks. ( 2.1 ) Colorectal cancer combination regimen 2: Irinotecan hydrochloride injection 180 mg/m 2 intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m 2 intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m 2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m 2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30. ( 2.1 ) Colorectal cancer single agent regimen 1: Irinotecan hydrochloride injection 125 mg/m 2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. ( 2.2 ) Colorectal cancer single agent regimen 2: Irinotecan hydrochloride injection 350 mg/m 2 intravenous infusion over 90 minutes on day 1 every 3 weeks. ( 2.2 )",
    "warningsAndPrecautions_original": "Irinotecan hydrochloride injection, USP is supplied as a sterile, pale yellow, clear, aqueous solution and is available in single-dose brown glass vials in the following package sizes:\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 PRESENTATION\n                                 \n                              \n                           \n                           \n                              \n                                 NDC CODE\n                                 \n                              \n                           \n                        \n                        \n                           \n                              2 mL-fill vial containing 40 mg/2 mL (20 mg/mL) irinotecan hydrochloride injection \n      \n                              \n                           \n                           \n                              NDC 68001-480-35 \n      \n                              \n                           \n                        \n                        \n                           \n                              5 mL-fill vial containing 100 mg/5 mL (20 mg/mL) irinotecan hydrochloride injection \n      \n                              \n                           \n                           \n                              NDC 68001-480-22 \n      \n                              \n                           \n                        \n                     \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Protect from light. Keep the vial in the carton until the time of use. \n  \n                       Inspect the vial for damage and visible signs of leaks before removing from the carton. If damaged, incinerate the unopened package.\n \n                  Irinotecan Hydrochloride is a hazardous drug. Follow special handling and disposal procedures\n \n  1.",
    "adverseReactions_original": "\u2022\u00a0Irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients."
}